Introduction
============

Innate immunity is a major part of the immune system, playing a significant role in the acute inflammation induced by microbial infection or tissue damage ([@b1-etm-08-06-1914]). Innate immune cells, including monocytes, dendritic cells and T cells, can be recognized by their germ line-encoded pattern recognition receptors (PRRs), which are responsible for sensing the structure of microbial species ([@b2-etm-08-06-1914]). PRRs have also been shown to recognize endogenous ligands released from damaged cells and tissues ([@b3-etm-08-06-1914]).

The Toll-like receptor (TLR) family is a well-characterized PRR family that is responsible for recognizing invading pathogens ([@b4-etm-08-06-1914]). TLR stimulation initiates a signal transduction pathway via the adaptor protein, MyD88, which induces the expression of proinflammatory cytokines, such as interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α ([@b5-etm-08-06-1914]). In total, 11 members constitute the human TLR family. Among them, TLR4 is a transmembrane protein specialized in the recognition of lipopolysaccharide (LPS), which is a component of gram-negative bacteria ([@b6-etm-08-06-1914]).

A previous study has demonstrated that the activation of TLR4 induces the expression of numerous proinflammatory molecules, which are essential in shaping the immune status of immune cells ([@b7-etm-08-06-1914]). However, the expression level variation of immune molecules within immune cells upon TLR4 stimulation remains unclear. In the current study, peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and stimulated by the TLR4 agonist, LPS, while the expression levels of various cytokines, chemokines, growth factors and kinases were screened. The aim of the present study was to confirm which types of immune molecules are involved in the activation of the TLR4 signaling pathway.

Materials and methods
=====================

Isolation and stimulation of PBMCs
----------------------------------

Heparinized venous blood samples were isolated from three healthy male volunteers (aged 25--28 years) and PBMCs were separated by density separation over Ficoll-Hypaque. After washing twice with phosphate buffered-saline, the PBMCs were plated into 24-well plates with a total number of 2×10^6^ cells/well. LPS was added to the PBMCs at a concentration of 100 ng/ml. Supernatants were collected at 4 h following stimulation for use in the antibody chip. The present study was approved by the Ethics Committee of West China Hospital, Sichuan University (Sichuan, China) and written informed consent was obtained from the patients.

RNA extraction and cDNA synthesis
---------------------------------

This procedure was performed as previously described ([@b8-etm-08-06-1914]). In brief, the total RNA from the PBMCs was extracted using a RNeasy mini kit (74104; Qiagen, Hilden, Germany) and quantified using a NanoDrop 3300 Fluorospectrometer (Thermo Fisher Scientific, Wilmington, DE, USA). cDNA was synthesized using a ReverTra Ace qPCR kit (FSQ-101; Toyobo, Kagoshima, Japan) and the reverse transcription (RT) conditions were as follows: 65°C for 5 min, 37°C for 15 min and 98°C for 5 min.

Quantification polymerase chain reaction (PCR)
----------------------------------------------

This procedure was performed as previously described ([@b8-etm-08-06-1914]). In brief, quantitative PCR (qPCR) was performed to amplify the synthesized cDNA using the RealMaster Mix Reagent (SYBR Green; FP202; Tiangen Biotech Co., Ltd., Beijing, China). An iCycler iQTM Optical Module (Beckman Coulter, Fullerton, CA, USA) was used for RT-qPCR under the following conditions: One cycle at 95°C for 30 sec, 40 cycles at 95°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec, followed by a melt curve between 55 and 95°C in 0.5°C-increments and 10-sec intervals. All the tests were performed in triplicate and the primers used are shown in [Table I](#tI-etm-08-06-1914){ref-type="table"}.

Antibody chip
-------------

The supernatants collected from the TLR4-stimulated and unstimulated PBMCs were arrayed for molecule secretion using the RayBio^®^ Human Antibody Array C-Series 1000 (RayBiotech, Inc., Norcross, GA, USA), according to the manufacturer's instructions. Blots were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis
--------------------

Data analysis was performed using the Bio-Rad iQ5 software (Bio-Rad Laboratories, Hercules, CA, USA), with glyceraldehyde 3-phosphate dehydrogenase as the internal control and normal PBMCs as the negative control. The results are expressed as the mean ± standard error of the mean and were analyzed using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). P\<0.05 and P\<0.001 were considered to indicate a statistically significant difference when compared with the control group. The figures were obtained using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

TLR4 agonist increases the expression levels of cytokines and chemokines
------------------------------------------------------------------------

RT-qPCR was performed to screen the expression levels of a number of cytokines and chemokines, in order to identify candidate genes responsible for the LPS-mediated changes in PBMCs. The expression level variation of a number of these genes may significantly affect the biological function of the PBMCs, induced by microenvironment or pathogen stimulation.

With regard to cytokine detection, the TLR4 agonist, LPS, was found to significantly increase the expression levels of several major cytokines (P\<0.001), including IL-1β, IL-8, IL-15, interferon (IFN)-β, IFN-γ, macrophage inflammatory protein (MIP)-3α and MIP-β. In addition, LPS slightly increased the expression level of IL-6 (P\<0.05). IL-23 was the only downregulated cytokine detected (P\<0.001; [Fig. 1A](#f1-etm-08-06-1914){ref-type="fig"}). During the chemokine assay, only the chemokine (C-C motif) ligand (CCL) 26, chemokine (C-X-C motif) ligand (CXCL) 2 and CXCL6 were found to be evidently enhanced upon LPS stimulation (P\<0.001), although CCL22, CCL24 and CCL28 were also found to be significantly different compared with the controls (P\<0.05; [Fig. 1B](#f1-etm-08-06-1914){ref-type="fig"}).

LPS stimulation enhances the expression levels of growth factors
----------------------------------------------------------------

Growth factors were screened to obtain their expression levels following LPS stimulation. The results indicated an evident upregulation of nuclear factor (NF)-κB, phosphatase and tensin homolog (PTEN), transforming growth factor (TGF)-β and TNF-α in the PBMCs activated by the TLR ligand (P\<0.001). The expression of c-Myc remained unchanged, while the expression of vascular endothelial growth factor (VEGF) was inhibited (P\<0.05; [Fig. 2](#f2-etm-08-06-1914){ref-type="fig"}).

Activation of the TLR4 signaling pathway has no evident effect on the expression levels of kinases
--------------------------------------------------------------------------------------------------

TLR4 agonist stimulation performed on PBMCs may induce the activation of protein kinases. Therefore, a number of protein kinase signaling pathways were analyzed in the study. The results indicated that the expression of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) was significantly enhanced in PBMCs following LPS stimulation (P\<0.001). However, cadherin-associated protein β (CTNNB), mitogen-activated protein kinase kinase kinase 1 (MAP3K1) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) expression levels remained unchanged during the detection. Notably, the expression levels of two important kinases, c-Jun N-terminal kinase (JNK) and MAP3K, were inhibited following LPS treatment (P\<0.05; [Fig. 3](#f3-etm-08-06-1914){ref-type="fig"}).

LPS induces the secretion of proinflammatory molecules
------------------------------------------------------

Supernatants collected from the LPS-treated and untreated PBMCs were analyzed to determine the secretion levels of major immune molecules using an antibody chip. A total of 20 proteins, including α-fetoprotein, albumin, E-selectin, intercellular adhesion molecule-1, IFN-α, IFN-γ, IL-10, IL-12, IL-18, IL-1β, IL-4, IL-5, IL-6, IL-8, monocyte chemoattractant protein (MCP)-1, MCP-3, MIP-1α, Notch-1, TGF-β and VEGF, were selected for analysis. The results revealed that only six of the aforementioned proteins were affected by TLR4 activation ([Fig 4](#f4-etm-08-06-1914){ref-type="fig"}). Among these, the secretion levels of IL-1β, IL-6 and MIP-1α were significantly enhanced (P\<0.001), while IL-8 secretion was moderately increased (P\<0.05). In addition, the secretion levels of MCP-1 and MCP-3 were inhibited.

Discussion
==========

Vertebrates have evolved systems of immune defense to eliminate invading pathogens. The innate immune system is the first line of the host defense against microorganisms and recognizes the conserved components of pathogens via pattern recognition receptors (PRRs) ([@b9-etm-08-06-1914]). Among the 11 human TLRs, TLR3, TLR7, TLR8 and TLR9 are expressed on the surface of endosomes, while TLR1, TLR2, TLR4, TLR5, TLR6, TLR10 and TLR11 are located on the cellular surface ([@b10-etm-08-06-1914]). TLR4 plays an important role in the protection against fungi by recognizing LPS components. Stimulation with a TLR4 agonist induces proinflammatory signals, as well as the production of type I IFNs ([@b11-etm-08-06-1914]).

In the present study, PBMCs were isolated from healthy volunteers and stimulated by the TLR4 agonist, LPS. At 4 h after the treatment, the supernatant and cellular RNA were isolated and assayed using an antibody chip and RT-qPCR, respectively. Using these methods, the immune molecules involved in the immunological signature of PBMCs can be identified and the TLR4 signaling pathway can be further understood. The molecules selected in the present study exhibit a number of important biological functions *in vivo*. In addition to increasing the expression levels of IL-8 and IL-6 ([@b12-etm-08-06-1914]), TLR4 agonist stimulation was found to influence numerous immunomodulatory factors. Among the cytokines examined, the expression levels of IL-1β, IL-6, IL-8, IL-15, IFN-β, IFN-γ, MIP-3α and MIP-3β increased markedly. During chemokine detection, the expression levels of CCL22, CCL24, CCL26, CXCL2 and CXCL6 were upregulated upon LPS stimulation. In addition, the expression levels of several growth factors, including NF-κB, PTEN, TNF-α and TGF-β, were enhanced. Detecting the expression levels of protein kinases, which play important roles in TLR-mediated biological functions, was important in this study. The expression level of pSTAT3 was found to increase in LPS-treated PBMCs, while the expression levels of CTNNB, MAP3K1 and PI3K remained unchanged in the treated and untreated groups. However, the expression of JNK was inhibited following LPS treatment. These results indicated that the activation of TLR4 had varying effects on the different kinase pathways. The cytokine levels were detected in the supernatants of LPS-treated PBMCs, and the secretion levels of IL-1β, IL-6, IL-8 and MIP-1α were found to be enhanced, indicating the important role of TLR4 in shaping the immune status of PBMCs.

Compared with previous studies, the present study analyzed a greater number of immune molecules that may be important in TLR-related functions. However, a limitation of the study was that the variation in the expression levels of immune molecules was only detected at a gene level. Future studies should analyze the association between these candidate immune molecules and TLR-mediated functions and should investigate the MEprotein expression levels.
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Oligonucleotides used in quantitative polymerase chain reaction analysis.

  Gene     Forward primer             Reverse primer              GenBank number
  -------- -------------------------- --------------------------- ----------------
  CCL5     GACACCACACCCTGCTGCT        TACTCCTTGATGTGGGCACG        NM_002985
  CCL7     AGCAGAGGCTGGAGAGCTACA      GGGTCAGCACAGATCTCCTTGT      NM_006273
  CCL8     GTTTCTGCAGCGCTTCTGTG       TGGCTGAGCAAGTCCCTGA         Y10802
  CCL15    CCTCTCCTGCCTCATGCTTATT     CTCTGTCTCTGCATCATTTGTGAA    U58914
  CCL17    CCATCGTTTTTGTAACTGTGCAG    TGCATTCTTCACTCTCTTGTTGTTG   NM_002987
  CCL22    TGCGCGTGGTGAAACACT         GGTTAGCAACACCACGCCA         NM_002990
  CCL24    AGCCTTCTGTTCCTTGGTGTCT     GGGAGAGGGTATGACCACAGAG      NM_002991
  CCL26    CCAAGACCTGCTGCTTCCAA       GAATTCATAGCTTCGCACCCA       NM_006072
  CCL28    CTCGCCATCGTGGCCTT          GCAATGGGAAGTATGGCTTCTG      AF220210
  c-Myc    CAAGACTCCAGCGCCTTCTC       GTTGAGTAACGAGCTGACCCC       AM393287
  CTNNB    CATCGTGAGGGCTTACTGGC       GAGCAAGGCAACCATTTTCTG       XM_006712984
  CXCL2    AGGTGAAGTCCCCCGGAC         GCCCATTCTTGAGTGTGGCT        NM_002089
  CXCL6    GCTGAGAGTAAACCCCAAAACG     GGAGCACTGCGGGCC             NM_002993
  GAPDH    GAAGGTGAAGGTCGGAGTC        GAAGATGGTGATGGGATTTC        J04038
  IFN-β    CAGCAATTTTCAGTGTCAGAAGCT   TCATCCTGTCCTTGAGGCAGT       M28622
  IFN-γ    CCAACGCAAAGCAATACATGA      CGCTTCCCTGTTTTAGCTGC        J00219
  IL-1β    ACGAATCTCCGACCACCACT       CCATGGCCACAACAACTGAC        M15330
  IL-2     CAAGAATCCCAAACTCACCAGG     GACACTGAAGATGTTTCAGTTCTGT   J00264
  IL-6     GACCCAACCACAAATGCCA        GTCATGTCCTGCAGCCACTG        M14584
  IL-7     ACCAGTAGAAGACAATTGCATC     CCAGGTTTTCATCATCTTCAGCT     NM_001199888
  IL-8     CTGGCCGTGGCTCTCTTG         CCTTGGCAAAACTGCACCTT        NM_000584
  IL-12    CGGTCATCTGCCGCAAA          CAAGATGAGCTATAGTAGCGGTCCT   M65272
  IL-15    GACCCCACCAAAGCTGGAC        TCACAGTGCTGCTGTCTGCTG       M90391
  IL-23    GAAGGCTCCGCTCTGCAAT        TCTGGGTCTTCTCGATGGCA        L06801
  IP-10    TGAAATTATTCCTGCAAGCCAA     CAGACATCTCTTCTCACCCTTCTTT   NM_001565
  JNK      GCTAATTCTGTACCAATGTC       GAAGAGTGCACGTCAGGAAC        NM_139049
  MAP3K    CCTGCTCGGTGCACGATGCTG      CTCTGTCTCTTCACGTGGCGG       NM_003954
  MAP3K1   CTTTTAAGTCAGAAGTTGCTG      CTTCTCCATTTTCAACCTGC        AF042838
  MIP-3α   TCCTGGCTGCTTTGATGTCA       TCAAAGTTGCTTGCTGCTTCTG      NM_004591
  MIP-3β   GGCACCAATGATGCTGAAGA       GAAGTTCCTCACGATGTACCCAG     NM_006274
  NF-κB    AGAGTGCTGGAGTTCAGGATA      AAGGTGGATGATTGCTAAGTGT      AJ271718
  PTEN     ACCATAACCCACCACAGC         CAGTTCGTCCCTTTCCAG          NM_058074
  PI3K     CCTGGGGGTTGGTGGCTGTTC      GTCTGGCTGGAATGATGCTATC      NM_006219
  STAT3    CCTACAAAGGGGACCCCATTGTAC   CAGGGAATTTGACCAGCAACC       NM_213662
  TGF-α    TATCGACATGGAGCTGGTGAAG     CAGCTTGGACAGGATCTGGC        X02812
  TNF-β    GGTGCTTGTTCCTCAGCCTC       CAGGCAGAAGAGCGTGGTG         M10988
  VEGF     GACTTGAGTTGGGAGGGGAA       GAGGCTCAGCGCCAGGGCTGGG      AF024710

CCL, chemokine (C-C motif) ligand; CTNNB, cadherin-associated protein β; CXCL, chemokine (C-X-C motif) ligand; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IFN, interferon; IL, interleukin; IP, interferon γ-induced protein; JNK, c-Jun N-terminal kinase; MAP3K, mitogen-activated protein kinase kinase kinase; MIP, macrophage inflammatory protein; NF, nuclear factor; PTEN, phosphatase and tensin homolog; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
